Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 330-336

  Baczek, Tomasz ^a   Konieczna, Lucyna ^a   Belka, Mariusz ^a   Maciejka Kapuścińska, Lucyna ^a   Wiśniewski, Jakub ^a   Niedźwiecki, Maciej ^a   Balcerska, Anna ^a   Adamkiewicz Drozyńska, Elzbieta ^a   Wachowiak, Jacek ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute myeloid leukemia (AML); Liquid chromatography coupled to mass spectrometry (LC MS); Pediatrics; Pharmacokinetic analysis; Topotecan

Indexed keywords

CLADRIBINE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; CLADRIBINE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIMIT OF DETECTION; LINEAR MODELS; METABOLIC CLEARANCE RATE; RECURRENCE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84866240831     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.05.012     Document Type: Article

References (22)

1. Goodman and Gilman's the Pharmacological Basis of Therapeutics 2010, McGraw-Hill Companies, Medical Publishing Division, New York. Twelfth ed. L. Brunton, B.A. Chabner, B. Knollman (Eds.).
2. Hycamtin, EMEA/H/C/000123-II/0059, Summary of Product Characteristics, 2010.
3. ®), a chase I and pharmacological study in adult patients with solid tumours. Eur. J. Cancer 1998, 34:1030-1035.
4. Zamboni W.C., Egorin M.J., Van Echo D.A., Day R.S., Meisenberg B.R., Brooks S.E., Doyle L.A., Nemieboka N.N., Dobson J.M., Tait N.S., Tkaczuk K.H. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J. Clin. Oncol. 2000, 18:3288-3294.
5. Hawkins D.S., Bradfield S., Whitlock J.A., Kraino M., Franklin J., Blaney S.M., Adamson P.C., Reaman G. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a children's oncology group study. Pediatr. Blood Cancer 2006, 47:790-794.
6. Freeman B.B., Iacono L.C., Panetta J.C., Gajjar A., Stewart C.F. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. Neuro Oncol. 2006, 8:89-95.
7. Waghner S., Erdlenbruch B., Längler A., Gnekow A., Kühl J., Albani M., Völpel S., Bucsky P., Emser A., Peters O., Wolff J.E.A. Oral topotecan in children with recurrent or progressive high-grade glioma. Cancer 2004, 100:1750-1757.
8. Inaba H., Stewart C.F., Crews K.R., Yang S., Pounds S., Pui Ch.H., Rubnitz J.E., Razzouk B.I., Ribeiro R.C. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer 2010, 116:98-105.
9. Davies B.E., Minthorn E.A., Dennis M.J., Rosing H., Beijnem J.H. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Pharm. Res. 1997, 14:1461-1465.
10. Gerrits C.J.H., Schellens J.H.M., Burris H., Eckardt J.R., Planting A.S.T., van der Burg M.E.L., Rodrigues G.I., Loos W.J., van Burden V., Hudson I., Von Hoff D.D., Verweij J. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin. Cancer Res. 1999, 5:69-75.
11. Schellens J.H.M., Creemers G.J., Beijnen J.H., Rosing H., de Boer-Dennert M., McDonald M., Davies B., Verweij J. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer 1996, 73:1268-1271.
12. Leger F., Loos W.J., Furcade J., Bugat R., Goffinet M., Mathijssen R.H.J., Verweij J., Sparreboom A., Chatelut E. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br. J. Cancer 2004, 10:343-347.
13. Schaiquevich P., Panetta J.C., Iacono L.C., Freeman B.B., Santana V.M., Gajjar A., Stewart C.F. Population pharmacokinetic analysis of topotecan in pediatric cancer patients. Clin. Cancer Res. 2007, 13:6703-6711.
14. Chen J., Balthasar J.P. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. J. Chromatogr. B 2005, 816:183-192.
15. Leggas M., Zhuang Y., Welden J., Self Z. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. J. Pharm. Sci. 2004, 93:2284-2295.
16. de Vries N.A., Ouwehand M., Buckle T., Beijnen J.H., van Tellingen O. Determination of topotecan in human and mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomed. Chromatogr. 2007, 21:1191-1200.
17. Hubbard K.E., Schaiquevich P., Bai F., Fraga Ch.H., Miller L., Panetta J.C., Stewart C.F. Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blond. Biomed. Chromatogr. 2009, 23:707-713.
18. Rosing H., van Zomeren D.M., Doyle E., ten Bokkel Huinink W.W., Schellens J.H.M., Bult A., Beijnem J.H. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. J. Chromatogr. B 1999, 727:191-203.
19. Rosing H., Herben V.M.M., van Gortel-van Zomeren D.M., Hop E., Kettenes-van den Bosch J.J., ten Bokkel Huinink W.W., Beijnen J.H. Isolation and structural confirmation of N-desmethyl topotecan a metabolite of topotecan. Cancer Chemother. Pharmacol. 1997, 39:498-504.
20. Arellano C., Gandia P., Bettuing L., Woodley J., Chatelut E. Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs. J. Chromatogr. B 2010, 878:645-652.
21. Food and Drug Administration Bioanalytical Method Validation May 2001, US Department of Health and Human Services, Centre for Drug Evaluation and Research (CDER).
22. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Gralnick C.R. Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 1985, 103:620-625.